336 related articles for article (PubMed ID: 28088251)
1. Lucerastat, an iminosugar with potential as substrate reduction therapy for glycolipid storage disorders: safety, tolerability, and pharmacokinetics in healthy subjects.
Guérard N; Morand O; Dingemanse J
Orphanet J Rare Dis; 2017 Jan; 12(1):9. PubMed ID: 28088251
[TBL] [Abstract][Full Text] [Related]
2. Lucerastat, an Iminosugar for Substrate Reduction Therapy: Pharmacokinetics, Tolerability, and Safety in Subjects With Mild, Moderate, and Severe Renal Function Impairment.
Guérard N; Zwingelstein C; Dingemanse J
J Clin Pharmacol; 2017 Nov; 57(11):1425-1431. PubMed ID: 28618006
[TBL] [Abstract][Full Text] [Related]
3. Impact of the organic cation transporter 2 inhibitor cimetidine on the single-dose pharmacokinetics of the glucosylceramide synthase inhibitor lucerastat in healthy subjects.
Boof ML; Halabi A; Ufer M; Dingemanse J
Eur J Clin Pharmacol; 2020 Mar; 76(3):431-437. PubMed ID: 31836927
[TBL] [Abstract][Full Text] [Related]
4. Lucerastat, an Iminosugar for Substrate Reduction Therapy: Tolerability, Pharmacodynamics, and Pharmacokinetics in Patients With Fabry Disease on Enzyme Replacement.
Guérard N; Oder D; Nordbeck P; Zwingelstein C; Morand O; Welford RWD; Dingemanse J; Wanner C
Clin Pharmacol Ther; 2018 Apr; 103(4):703-711. PubMed ID: 28699267
[TBL] [Abstract][Full Text] [Related]
5. The effect of the glucosylceramide synthase inhibitor lucerastat on cardiac repolarization: results from a thorough QT study in healthy subjects.
Mueller MS; Sidharta PN; Voors-Pette C; Darpo B; Xue H; Dingemanse J
Orphanet J Rare Dis; 2020 Oct; 15(1):303. PubMed ID: 33109218
[TBL] [Abstract][Full Text] [Related]
6. Safety, Tolerability, and Pharmacokinetic Profile of the Novel Translocator Protein 18 kDa Antagonist ONO-2952 in Healthy Volunteers.
Suto F; Wood AT; Kobayashi M; Komaba J; Duffy K; Bruce M
Clin Ther; 2015 Sep; 37(9):2071-84. PubMed ID: 26249232
[TBL] [Abstract][Full Text] [Related]
7. Safety, tolerability and pharmacokinetics of trimebutine 3-thiocarbamoylbenzenesulfonate (GIC-1001) in a randomized phase I integrated design study: single and multiple ascending doses and effect of food in healthy volunteers.
Paquette JM; Rufiange M; Iovu Niculita M; Massicotte J; Lefebvre M; Colin P; Telmat A; Ranger M
Clin Ther; 2014 Nov; 36(11):1650-64. PubMed ID: 25224876
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics, Safety Profile, and Tolerability of Tetramethylpyrazine Nitrone Tablets After Single and Multiple Ascending Doses in Healthy Chinese Volunteers.
Zhu G; Wang L; Zhong S; Han S; Peng H; Tong M; He X
Eur J Drug Metab Pharmacokinet; 2024 Mar; 49(2):207-217. PubMed ID: 38381348
[TBL] [Abstract][Full Text] [Related]
9. Safety and Pharmacokinetics of HRS-2261, a P2X3 Receptor Antagonist, in Healthy Subjects: A Randomized, Double-Blind, Placebo-Controlled Phase 1 Study.
Fan Y; Zhang X; Zhang Q; Zheng L; Zhou R; Sun C; Wang X; Song K; He Z; Wang H; Zhang Q; Hu W
Clin Pharmacokinet; 2024 Mar; 63(3):293-302. PubMed ID: 38198010
[TBL] [Abstract][Full Text] [Related]
10. Effects of Single and Multiple Ascending Doses of BI 1358894 in Healthy Male Volunteers on Safety, Tolerability and Pharmacokinetics: Two Phase I Partially Randomised Studies.
Fuertig R; Goettel M; Herich L; Hoefler J; Wiebe ST; Sharma V
CNS Drugs; 2023 Dec; 37(12):1081-1097. PubMed ID: 38019355
[TBL] [Abstract][Full Text] [Related]
11. An open-label study to determine the pharmacokinetics and safety of migalastat HCl in subjects with impaired renal function and healthy subjects with normal renal function.
Johnson FK; Mudd PN; DiMino T; Vosk J; Sitaraman S; Boudes P; France N; Barlow C
Clin Pharmacol Drug Dev; 2015 Jul; 4(4):256-61. PubMed ID: 27136905
[TBL] [Abstract][Full Text] [Related]
12. Safety, Tolerability, Pharmacokinetics, and Immunogenicity of a Novel Recombination Human Nerve Growth Factor in Healthy Chinese Subjects.
Shen Q; Zhang M; Jin Y; Di X; Liu R; Wang Z
CNS Drugs; 2023 Mar; 37(3):231-242. PubMed ID: 36811740
[TBL] [Abstract][Full Text] [Related]
13. Safety, tolerability, and pharmacokinetics of the novel pan-phosphodiesterase inhibitor ZSP1601 in healthy subjects: a double-blinded, placebo-controlled first-in-human single-dose and multiple-dose escalation and food effect study.
Zhu X; Wu M; Wang H; Li H; Lin J; Peng Y; Hu Y; Li C; Ding Y
Expert Opin Investig Drugs; 2021 May; 30(5):579-589. PubMed ID: 33682556
[No Abstract] [Full Text] [Related]
14. Pharmacokinetic and pharmacodynamic assessments of the dipeptidyl peptidase-4 inhibitor PHX1149: double-blind, placebo-controlled, single- and multiple-dose studies in healthy subjects.
O'Farrell AM; van Vliet A; Abou Farha K; Cherrington JM; Campbell DA; Li X; Hanway D; Li J; Guler HP
Clin Ther; 2007 Aug; 29(8):1692-705. PubMed ID: 17919550
[TBL] [Abstract][Full Text] [Related]
15. Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of Benfotiamine in Healthy Subjects.
Sheng L; Cao W; Lin P; Chen W; Xu H; Zhong C; Yuan F; Chen H; Li H; Liu C; Yang M; Li X
Drug Des Devel Ther; 2021; 15():1101-1110. PubMed ID: 33727798
[TBL] [Abstract][Full Text] [Related]
16. Effects of food intake on the pharmacokinetic properties of mirabegron oral controlled-absorption system: a single-dose, randomized, crossover study in healthy adults.
Lee J; Zhang W; Moy S; Kowalski D; Kerbusch V; van Gelderen M; Sawamoto T; Grunenberg N; Keirns J
Clin Ther; 2013 Mar; 35(3):333-41. PubMed ID: 23497763
[TBL] [Abstract][Full Text] [Related]
17. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
Chen C; Bujanover S; Kareht S; Rapoport AM
Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
[TBL] [Abstract][Full Text] [Related]
18. A Phase 1, Randomised, Placebo-Controlled, Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of Cannabidiol in Fed Healthy Volunteers.
Perkins D; Butler J; Ong K; Nguyen TH; Cox S; Francis B; Mcintosh M; Lilley B
Eur J Drug Metab Pharmacokinet; 2020 Oct; 45(5):575-586. PubMed ID: 32409982
[TBL] [Abstract][Full Text] [Related]
19. Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of Vixotrigine in Healthy Volunteers.
Naik H; Steiner DJ; Versavel M; Palmer J; Fong R
Clin Transl Sci; 2021 Jul; 14(4):1272-1279. PubMed ID: 33278330
[TBL] [Abstract][Full Text] [Related]
20. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SPH3127: A Phase I, Randomized, Double-Blind, Placebo-Controlled Trial.
Jing S; Xu R; Yang K; Liu W; Zhang L; Ke Y; Xia G; Lin Y
Clin Ther; 2021 Apr; 43(4):735.e1-735.e14. PubMed ID: 33653620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
